Blaze Bioscience Announces Publication of Tumor Paint BLZ-100 Data in Cancer Research

Findings provide validation of BLZ-100 in the veterinary clinical setting

SEATTLE–(BUSINESS WIRE)–Blaze
Bioscience
, the Tumor Paint Company®, a biotechnology
company focused on guided cancer therapy, today announced the
publication of a manuscript in Cancer Research validating the
preclinical utility of Tumor Paint BLZ-100 in canine patients with
naturally occurring solid tumors. The article entitled “Preclinical
validation of the utility of BLZ-100 in providing fluorescence contrast
for imaging canine spontaneous solid tumors” by Fidel et al, is
available in the October 15, 2015 issue of Cancer Research and
online at http://cancerres.aacrjournals.org.

Tumor Paint BLZ-100 was administered before surgery to dogs with a
variety of naturally occurring tumors. Fluorescent contrast was assessed ex
vivo
and intraoperatively in a subset of canine patients. Proof of
concept for the utility of BLZ-100 was achieved in a number of cancer
types most notably in subcutaneous soft tissue sarcomas. The study was
fully funded by the National Cancer Institute (NCI) through a Phase 1
Small Business Innovation Research (SBIR) contract1 and was
conducted at Washington State University’s College of Veterinary
Medicine.

“These findings provided key information to support clinical translation
of BLZ-100,” said Julie Novak, Blaze Bioscience VP of Research and
Principal Investigator of the NCI contract. “Success of this canine
study led to the follow-on NCI SBIR Phase II contract and the recently
announced clinical trial in soft tissue sarcoma. This publication is an
important validation of the Tumor Paint platform and Blaze’s continued
commitment to steadily advance our pipeline.”

About BLZ-100

BLZ-100 is the first product candidate from Blaze’s Tumor Paint platform
and consists of an Optide (optimized peptide), which binds and
internalizes into cancer cells, and a fluorescent dye, which emits light
in the near-infrared range. Tumor Paint products are designed to provide
real-time, high-resolution intraoperative visualization of cancer cells,
enabling more precise, complete resection of cancer throughout surgery.
Preclinical utility of Tumor Paint technology has been demonstrated in a
wide range of cancer types. BLZ-100 is currently in multiple Phase 1
proof-of-concept clinical studies to evaluate the safety and imaging
characteristics of BLZ-100 in solid tumor cancers, including brain,
breast, lung, prostate, colorectal, and sarcoma.

About Blaze Bioscience

Blaze Bioscience, Inc. is a privately held biotechnology company focused
on guided cancer therapy. Blaze was founded in 2010 by Dr. Jim Olson, a
pediatric neuro-oncologist at the Fred Hutchinson Cancer Research Center
and Seattle Children’s Hospital, and Heather Franklin, a former member
of the executive management team at ZymoGenetics. Blaze is working to
develop Tumor Paint products and Optide-based therapeutics. Surgery is
first-line therapy for most solid tumor cancers and Tumor Paint products
intend to improve cancer surgery by providing real-time, high-resolution
visualization of cancer cells throughout surgery. The ability to see
cancer cells in real time and high resolution throughout surgery should
enable better detection and more complete and precise surgical removal
of cancer—while sparing surrounding normal tissue. In addition to the
Tumor Paint platform, Blaze is collaborating with the Fred Hutchinson
Cancer Research Center to discover and develop products based on knottin
peptides as part of the Optides platform. This program extends the
expertise gained in developing the Tumor Paint platform to optimized
knottin peptides for therapeutic and imaging applications. For
additional information, please visit www.blazebioscience.com.

1 This project has been funded in whole with Federal funds
from National Cancer Institute, National Institutes of Health,
Department of Health and Human Services, under Contract No.
HHSN261201200054C.

Contacts

Media:
Blaze Bioscience, Inc.
Lauren Nelson, 206-535-8144
lauren.nelson@blazebioscience.com
or
Investor
Relations
SOS Communications LLC
Susan Specht Oram,
360-535-3035
spechtoram@gmail.com